基于移植物 CD8 T 细胞的风险系统可预测以抗胸腺细胞球蛋白为基础的髓溶性单倍体外周血干细胞移植的存活率

IF 4.6 2区 医学 Q2 IMMUNOLOGY Clinical & Translational Immunology Pub Date : 2024-01-12 DOI:10.1002/cti2.1484
Panpan Zhu, Luxin Yang, Yibo Wu, Jimin Shi, Xiaoyu Lai, Lizhen Liu, Yishan Ye, Jian Yu, Yanmin Zhao, Xiaolin Yuan, Huarui Fu, Zhen Cai, He Huang, Yi Luo
{"title":"基于移植物 CD8 T 细胞的风险系统可预测以抗胸腺细胞球蛋白为基础的髓溶性单倍体外周血干细胞移植的存活率","authors":"Panpan Zhu,&nbsp;Luxin Yang,&nbsp;Yibo Wu,&nbsp;Jimin Shi,&nbsp;Xiaoyu Lai,&nbsp;Lizhen Liu,&nbsp;Yishan Ye,&nbsp;Jian Yu,&nbsp;Yanmin Zhao,&nbsp;Xiaolin Yuan,&nbsp;Huarui Fu,&nbsp;Zhen Cai,&nbsp;He Huang,&nbsp;Yi Luo","doi":"10.1002/cti2.1484","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>This study investigated the cellular composition of peripheral blood grafts for anti-thymocyte globulin (ATG)-based myeloablative haploidentical haematopoietic stem cell transplantation (haplo-HSCT).</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Clinical characteristics were retrospectively evaluated in a training cohort with ATG-based myeloablative haplo-HSCT between January 2016 and February 2020 and confirmed in a validation cohort between March 2020 and June 2021.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A higher dose of graft CD8<sup>+</sup> T cells (≥ 0.85 × 10<sup>8</sup> kg<sup>−1</sup>) was significantly improved overall survival (OS; hazard ratio [HR], 1.750; <i>P</i> = 0.002) and disease-free survival (DFS; HR, 1.751; <i>P</i> &lt; 0.001) in the training cohort, according to multivariate Cox regression analysis. Higher doses of mononuclear cells (MNCs) demonstrated better OS (HR, 1.517; <i>P</i> = 0.038) and DFS (HR, 1.532; <i>P</i> = 0.027). Older patient age (&gt; 46 years), older donor age (≥ 50 years) and a higher refined disease risk index (rDRI) were also related to OS. A graft CD8<sup>+</sup> T-cell risk system based on graft CD8<sup>+</sup> T-cell dose, donor age and rDRI was constructed using a nomogram model after LASSO Cox regression analysis. It showed acceptable discrimination, with a C-index of 0.62 and 0.63, respectively. Graft CD8<sup>+</sup> T-cell dose was negatively correlated with donor age (<i>P</i> &lt; 0.001) and positively correlated with a higher lymphocyte percentage in the peripheral blood before mobilisation (<i>P</i> &lt; 0.001).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>A higher CD8<sup>+</sup> T-cell dose in peripheral blood-derived grafts improves patients' survival with ATG-based myeloablative haplo-HSCT. Younger donors with higher lymphocyte percentages improved patients' survival with an intermediate rDRI risk.</p>\n </section>\n </div>","PeriodicalId":152,"journal":{"name":"Clinical & Translational Immunology","volume":"13 1","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2024-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cti2.1484","citationCount":"0","resultStr":"{\"title\":\"Graft CD8 T-cell-based risk system predicts survival in antithymocyte globulin-based myeloablative haploidentical peripheral blood stem cell transplantation\",\"authors\":\"Panpan Zhu,&nbsp;Luxin Yang,&nbsp;Yibo Wu,&nbsp;Jimin Shi,&nbsp;Xiaoyu Lai,&nbsp;Lizhen Liu,&nbsp;Yishan Ye,&nbsp;Jian Yu,&nbsp;Yanmin Zhao,&nbsp;Xiaolin Yuan,&nbsp;Huarui Fu,&nbsp;Zhen Cai,&nbsp;He Huang,&nbsp;Yi Luo\",\"doi\":\"10.1002/cti2.1484\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Objective</h3>\\n \\n <p>This study investigated the cellular composition of peripheral blood grafts for anti-thymocyte globulin (ATG)-based myeloablative haploidentical haematopoietic stem cell transplantation (haplo-HSCT).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>Clinical characteristics were retrospectively evaluated in a training cohort with ATG-based myeloablative haplo-HSCT between January 2016 and February 2020 and confirmed in a validation cohort between March 2020 and June 2021.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>A higher dose of graft CD8<sup>+</sup> T cells (≥ 0.85 × 10<sup>8</sup> kg<sup>−1</sup>) was significantly improved overall survival (OS; hazard ratio [HR], 1.750; <i>P</i> = 0.002) and disease-free survival (DFS; HR, 1.751; <i>P</i> &lt; 0.001) in the training cohort, according to multivariate Cox regression analysis. Higher doses of mononuclear cells (MNCs) demonstrated better OS (HR, 1.517; <i>P</i> = 0.038) and DFS (HR, 1.532; <i>P</i> = 0.027). Older patient age (&gt; 46 years), older donor age (≥ 50 years) and a higher refined disease risk index (rDRI) were also related to OS. A graft CD8<sup>+</sup> T-cell risk system based on graft CD8<sup>+</sup> T-cell dose, donor age and rDRI was constructed using a nomogram model after LASSO Cox regression analysis. It showed acceptable discrimination, with a C-index of 0.62 and 0.63, respectively. Graft CD8<sup>+</sup> T-cell dose was negatively correlated with donor age (<i>P</i> &lt; 0.001) and positively correlated with a higher lymphocyte percentage in the peripheral blood before mobilisation (<i>P</i> &lt; 0.001).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>A higher CD8<sup>+</sup> T-cell dose in peripheral blood-derived grafts improves patients' survival with ATG-based myeloablative haplo-HSCT. Younger donors with higher lymphocyte percentages improved patients' survival with an intermediate rDRI risk.</p>\\n </section>\\n </div>\",\"PeriodicalId\":152,\"journal\":{\"name\":\"Clinical & Translational Immunology\",\"volume\":\"13 1\",\"pages\":\"\"},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2024-01-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cti2.1484\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical & Translational Immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cti2.1484\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical & Translational Immunology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cti2.1484","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的 本研究调查了基于抗胸腺细胞球蛋白(ATG)的髓鞘消融性单倍体造血干细胞移植(haplo-HSCT)外周血移植物的细胞组成。 方法 回顾性评估2016年1月至2020年2月期间基于ATG的髓鞘消融单倍体造血干细胞移植培训队列的临床特征,并在2020年3月至2021年6月期间的验证队列中进行确认。 结果 根据多变量 Cox 回归分析,在训练队列中,较高剂量的移植物 CD8+ T 细胞(≥ 0.85 × 108 kg-1)可显著改善总生存期(OS;危险比 [HR],1.750;P = 0.002)和无病生存期(DFS;HR,1.751;P < 0.001)。单核细胞(MNC)剂量越高,OS(HR,1.517;P = 0.038)和DFS(HR,1.532;P = 0.027)越好。患者年龄较大(46 岁)、供体年龄较大(≥ 50 岁)和疾病风险指数(rDRI)较高也与 OS 有关。经过 LASSO Cox 回归分析后,使用提名图模型构建了基于移植物 CD8+ T 细胞剂量、供体年龄和 rDRI 的移植物 CD8+ T 细胞风险系统。该系统显示了可接受的区分度,C 指数分别为 0.62 和 0.63。移植物 CD8+ T 细胞剂量与供体年龄呈负相关(P < 0.001),与动员前外周血中较高的淋巴细胞百分比呈正相关(P < 0.001)。 结论 外周血移植物中 CD8+ T 细胞剂量越高,基于 ATG 的髓脱性单倍体造血干细胞移植患者的存活率越高。淋巴细胞百分比较高的年轻供者可提高患者的存活率,但 rDRI 风险居中。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Graft CD8 T-cell-based risk system predicts survival in antithymocyte globulin-based myeloablative haploidentical peripheral blood stem cell transplantation

Objective

This study investigated the cellular composition of peripheral blood grafts for anti-thymocyte globulin (ATG)-based myeloablative haploidentical haematopoietic stem cell transplantation (haplo-HSCT).

Methods

Clinical characteristics were retrospectively evaluated in a training cohort with ATG-based myeloablative haplo-HSCT between January 2016 and February 2020 and confirmed in a validation cohort between March 2020 and June 2021.

Results

A higher dose of graft CD8+ T cells (≥ 0.85 × 108 kg−1) was significantly improved overall survival (OS; hazard ratio [HR], 1.750; P = 0.002) and disease-free survival (DFS; HR, 1.751; P < 0.001) in the training cohort, according to multivariate Cox regression analysis. Higher doses of mononuclear cells (MNCs) demonstrated better OS (HR, 1.517; P = 0.038) and DFS (HR, 1.532; P = 0.027). Older patient age (> 46 years), older donor age (≥ 50 years) and a higher refined disease risk index (rDRI) were also related to OS. A graft CD8+ T-cell risk system based on graft CD8+ T-cell dose, donor age and rDRI was constructed using a nomogram model after LASSO Cox regression analysis. It showed acceptable discrimination, with a C-index of 0.62 and 0.63, respectively. Graft CD8+ T-cell dose was negatively correlated with donor age (P < 0.001) and positively correlated with a higher lymphocyte percentage in the peripheral blood before mobilisation (P < 0.001).

Conclusion

A higher CD8+ T-cell dose in peripheral blood-derived grafts improves patients' survival with ATG-based myeloablative haplo-HSCT. Younger donors with higher lymphocyte percentages improved patients' survival with an intermediate rDRI risk.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Clinical & Translational Immunology
Clinical & Translational Immunology Medicine-Immunology and Allergy
CiteScore
12.00
自引率
1.70%
发文量
77
审稿时长
13 weeks
期刊介绍: Clinical & Translational Immunology is an open access, fully peer-reviewed journal devoted to publishing cutting-edge advances in biomedical research for scientists and physicians. The Journal covers fields including cancer biology, cardiovascular research, gene therapy, immunology, vaccine development and disease pathogenesis and therapy at the earliest phases of investigation.
期刊最新文献
Autologous Epstein-Barr virus-specific adoptive T-cell therapy in a patient with lupus nephritis. The contribution of the CRP/CD64 axis to renal cancer progression by inducing protumor activation of tumor-associated macrophages. Natural killer cell antibody-dependent cellular cytotoxicity to Plasmodium falciparum is impacted by cellular phenotypes, erythrocyte polymorphisms, parasite diversity and intensity of transmission Naturally acquired adaptive immunity to Streptococcus pneumoniae is impaired in rheumatoid arthritis patients Inhibitory effect of hydroxychloroquine on glucocorticoid-induced osteoporosis in lupus therapy
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1